Navigation Links
Kyphon Stockholders Approve Merger with Medtronic
Date:10/16/2007

SUNNYVALE, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Kyphon Inc. (Nasdaq: KYPH) announced today that its stockholders approved the adoption of the merger agreement with Medtronic, Inc. (NYSE: MDT) at a special meeting of stockholders held today.

As previously announced, on July 26, 2007, Kyphon entered into a definitive merger agreement with Medtronic, pursuant to which Medtronic agreed to acquire all of the outstanding shares of Kyphon common stock for $71.00 per share in cash. Consummation of the transaction remains subject to customary closing conditions, including clearance from antitrust authorities in Portugal and Turkey. The initial review periods in both of these jurisdictions are scheduled to expire later this month unless the antitrust authorities extend the relevant periods. The parties intend to consummate the transaction reasonably promptly following the receipt of the required antitrust clearances in Portugal and Turkey and the satisfaction of the other customary closing conditions contained in the merger agreement, but in no event prior to November 1.

About Kyphon Inc.

Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) (F.A.D.(TM)) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression (IPD(R)) procedure for treating the symptoms of lumbar spinal stenosis. More information about the company and its products can be found at http://www.kyphon.com and its balloon kyphoplasty patient education Web site, http://www.spinalfracture.com.

Kyphon and IPD are registered trademarks, and Functional Anaesthetic Discography and F.A.D. are trademarks, of Kyphon Inc.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, about the completion of the merger. Forward-looking statements are based on management's current preliminary expectations and are subject to risks, uncertainties and assumptions, which may cause Kyphon's actual results to differ materially from the statements contained herein. Factors that could cause actual results to differ materially from management's current expectations include, without limitation, the potential inability to obtain the regulatory clearances required to complete the merger, or to do so in a timely manner, and the possibility that other conditions to completion of the merger may not be satisfied. Additional factors that may affect future results are contained in Kyphon's periodic filings with the SEC, which are available at the SEC's Web site http://www.sec.gov. Kyphon undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.

KYPHG


'/>"/>
SOURCE Kyphon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. UW-Madison approves new research institute
2. FDA approves GEs heart-imaging technology
3. Senate approves bill to expand stem cell funding
4. FDA approves advanced digital mammography system
5. Building commission approves Institutes for Discovery
6. Seven good reasons to approve the Institutes for Discovery
7. Genzyme acquistion of Bone Care approved, significant impact forecast
8. UW Board of Regents approves $134 million medical research facility
9. FDA approves Bone Cares Hectorol for treatment of kidney disease
10. Technology and mergers: Getting the strategic applications
11. AT&T - BellSouth merger: Revestiture continues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... Irvine, ca (PRWEB) , ... October 12, 2017 ... ... for the Surgical Wound Market with the addition of its newest module, US ... the $1.2B market for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and ...
(Date:10/11/2017)... ... ... eye wash is a basic first aid supply for any work environment, but most personal ... rinse first if a dangerous substance enters both eyes? It’s one less decision, and likely ... dual eye piece. , “Whether its dirt and debris, or an acid or alkali, getting ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are ... 5.5 million people each year. Especially those living in larger cities are affected by ... in one of the most pollution-affected countries globally - decided to take action. , ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... FirstHand program has won a US2020 STEM Mentoring Award. Representatives of the FirstHand ... Excellence in Volunteer Experience from US2020. , US2020’s mission is to change the ...
Breaking Biology Technology:
(Date:8/23/2017)... -- The general public,s help is being enlisted in what,s thought to be ... on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the largest study ... gut. The project's goal is to help advance scientific knowledge of the ... ...
(Date:7/20/2017)... 20, 2017 Delta (NYSE: DAL ) customers now ... aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft at ... Delta,s biometric boarding pass experience ... is now integrated into the boarding process to allow eligible Delta SkyMiles ...
(Date:6/23/2017)... and ITHACA, N.Y. , June 23, ... University, a leader in dairy research, today announced a ... to help reduce the chances that the global milk ... of this dairy project, Cornell University has become the ... the Food Supply Chain, a food safety initiative that ...
Breaking Biology News(10 mins):